Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Patients
Latest Information Update: 25 Apr 2023
At a glance
- Drugs Tilvestamab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
Most Recent Events
- 18 Apr 2023 Status changed from recruiting to discontinued.
- 20 May 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04893551).
- 17 May 2021 Status changed from planning to recruiting.